Kevin James Horgan MD

Clinical Pharmacology, Clinical Informatics

Advisor, Liquid Biosciences, Aliso Viejo, California

200 Medical 530 420 120 Plz# 365Los Angeles, CA 90095
Phone+1 310-794-9718
Fax+1 310-301-8751

Dr. Horgan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Horgan's full profile Already have an account?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1991 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1988
University College Cork Faculty of MedicineClass of 1982

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1991 - 2020
MD State Medical License 1990 - 1992

Clinical Trials

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

18 citations
Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Paul Baverel, Lorin Roskos, Manasa Tatipalli, Nancy Lee, Paul K. Stockman
Clinical and Translational Science. 2019-09-01
13 citations
Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease.
Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A. Pergam, Michele E. Lloid
Biology of Blood and Marrow Transplantation. 2012-06-01
372 citations
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson
Gastroenterology. 2009-10-01

Press Mentions

Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative ColitisJanuary 3rd, 2019
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational UpdatesNovember 8th, 2018
Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical OfficerOctober 22nd, 2018